Galmed Develops New Aramchol Formulation for CNS Diseases

Written by Emily J. Thompson, Senior Investment Analyst

Source: Newsfilter

Updated: Apr 09 2026

0mins

GLMD+2.17%

Should l Buy GLMD?

Source: Newsfilter

Breakthrough Drug Development: Galmed, in collaboration with Barcode Nanotech, has developed a new formulation of Aramchol that can cross the blood-brain barrier, potentially serving as a disease-modifying therapy for chronic CNS diseases like Parkinson's, addressing a significant unmet need in the market.
Targeting Mechanism Innovation: The new formulation encapsulates Aramchol in lipid nanoparticles and is administered via subcutaneous injection, ensuring effective delivery to the brain, which could significantly improve the pathological state of Parkinson's patients and slow disease progression.
Preclinical Research Results: In vitro studies demonstrate that Aramchol effectively down-regulates α-synuclein aggregation in a dose-dependent manner, indicating its promising potential as the first drug targeting this pathway for neurodegenerative diseases associated with α-synuclein.
Future Clinical Plans: Galmed plans to initiate Phase 1b/2 clinical trials for Aramchol in Parkinson's patients in H2 2026, aiming to further validate its efficacy and potentially provide new treatment options for patients.

Trade with 70% Backtested Accuracy

Stop guessing "Should I Buy GLMD?" and start using high-conviction signals backed by rigorous historical data.

Analyst Views on GLMD

About GLMD

Galmed Pharmaceuticals Ltd. is an Israel-based biopharmaceutical company dedicated to the development of therapeutics for the treatment of liver diseases. The Company is focused its research and development efforts on addressing unmet medical needs in the field of liver health. The Company's flagship product is Aramchol, a first-in-class synthetic fatty acid-bile acid conjugate molecule. Aramchol is aimed to be effective in the treatment of non-alcoholic steatohepatitis (NASH) in patients who are overweight or obese and have prediabetes or type II diabetes mellitus. The Company's drug aims to be efficient treatment of NASH, a chronic liver disease characterized by fat accumulation, inflammation, and fibrosis, which can lead to cirrhosis and liver cancer if left untreated.

About the author

Emily J. Thompson

Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.

Galmed Partners with Tel Aviv University to Develop New Therapy

4 days agoNASDAQ.COM

Collaboration Agreement: Galmed Pharmaceuticals has signed a collaboration agreement with Ramot at Tel Aviv University to evaluate the potential of Aramchol in treating metastatic brain cancer, marking a strategic expansion into oncology.
Drug Mechanism Analysis: Originally developed as an SCD1 inhibitor for liver disease, Aramchol is now being repurposed for breast cancer brain metastasis treatment, demonstrating its potential by downregulating SCD1 to prevent further metastasis in cancer cells.
Research Support: Studies from Tel Aviv University indicate that p53 mutations lead to metabolic adaptations associated with SCD1 upregulation, and Galmed plans to validate Aramchol's efficacy in p53-deficient brain metastasis using advanced preclinical testing systems.
Clinical Work Advancement: This collaboration will support Galmed's ongoing clinical research at Virginia Commonwealth University, particularly in colorectal cancers where p53 mutations are prevalent, providing a new research direction for Aramchol's application.

Galmed Partners with Tel Aviv University to Develop New Cancer Therapy

5 days agoPRnewswire

Research Collaboration Agreement: Galmed Pharmaceuticals has signed a research collaboration agreement with Ramot at Tel Aviv University to evaluate its brain-penetrating SCD1 inhibitor, Aramchol, as a targeted therapy for metastatic brain cancer, marking a strategic expansion into cancer treatment.
Combining Genomics and Modeling: By collaborating with the Ben-David Lab and Satchi-Fainaro Lab, Galmed aims to leverage advanced 3D in vitro and in vivo modeling techniques to validate Aramchol's efficacy in treating p53-deficient brain metastases, potentially providing critical data support for clinical applications.
Metabolic Adaptation Research: Studies indicate that p53 inactivation induces metabolic adaptations in tumors, facilitating metastasis in the lipid-rich brain microenvironment, and Aramchol's downregulation of SCD1 could represent a novel treatment option for this metabolic-dependent brain tumor, holding significant clinical implications.
Innovative Treatment Prospects: Galmed CEO Allen Baharaff emphasized that the discovery of p53 inactivation driving brain metastasis opens up innovative therapeutic opportunities for Aramchol, and this collaboration will advance its development in metastatic cancers, addressing the high unmet needs of patient populations.

Galmed Partners with Tel Aviv University to Develop Aramchol for Brain Metastases

5 days agoNewsfilter

Breakthrough in Drug Development: Galmed announced a collaboration with Ramot at Tel Aviv University to utilize Aramchol as a first-in-class brain-penetrant SCD1 inhibitor targeting metastatic brain cancer, potentially offering an innovative therapy for this lethal condition.
Survival Rate Challenge: Patients with brain metastases have a two-year survival rate below 10%, and despite various treatment modalities, there is an urgent need for new therapies, making the development of Aramchol crucial for improving outcomes.
Research Collaboration Advantage: By leveraging the genomic expertise of the Ben-David Lab and the 3D modeling capabilities of the Satchi-Fainaro Lab, Galmed aims to validate Aramchol's efficacy in treating p53-deficient brain metastases, paving the way for clinical applications.
Strategic Significance: This collaboration not only lays the groundwork for Aramchol's clinical development but also may provide new therapeutic insights for other cancer types, highlighting Galmed's innovative potential in oncology.

Galmed Pharmaceuticals Shares Surge 85% on New Drug Formulation Launch

Apr 09 2026stocktwits

Stock Surge: Galmed Pharmaceuticals (GLMD) shares soared over 85% in pre-market trading on Thursday, surpassing $1 for the first time since December 19, indicating strong market enthusiasm for the new drug formulation and reflecting investor optimism about the company's future potential.
New Drug Formulation: The newly launched Aramchol formulation utilizes lipid nanoparticles delivered via injection, designed to cross the blood-brain barrier, representing a significant technological breakthrough that could provide new treatment options for central nervous system disorders like Parkinson's disease, showcasing the company's innovative capabilities in biotechnology.
Market Performance: GLMD's stock has gained 27% over the past five sessions, and the robust pre-market performance further solidifies investor confidence in the company, potentially attracting more institutional investors' interest in the stock.
Collaborative Development: The formulation was developed in collaboration with Barcode Nanotech, highlighting Galmed's strategic partnerships in technology development aimed at addressing unmet medical needs through innovative drugs, thereby enhancing its competitive position in the market.

Galmed Pharmaceuticals Announces Breakthrough in CNS Drug Development

Apr 09 2026PRnewswire

Breakthrough Drug Formulation: Galmed Pharmaceuticals, in collaboration with Barcode Nanotech, has developed a new formulation of Aramchol that penetrates the blood-brain barrier, marking a significant advancement in the treatment of Parkinson's disease and other CNS disorders, potentially addressing the current lack of effective therapies.
Technological Innovation: This formulation utilizes lipid nanoparticles for subcutaneous injection, combined with AI analysis tools to optimize drug delivery, enhancing the targeting and efficacy of the treatment, which could significantly improve patient outcomes.
Preclinical Data Support: Preliminary in vitro data indicates that Aramchol dose-dependently down-regulates αSyn aggregation without associated toxicity, providing strong evidence for its safety and efficacy as a potential therapeutic agent.
Future Clinical Trial Plans: Galmed plans to initiate Phase 1b/2 clinical trials in Parkinson's patients in H2 2026, which, if successful, will introduce new treatment options in the field and further solidify the company's position in the biopharmaceutical industry.